April 30 1M for the year ended.

Related StoriesLilly, ImaginAb partner to review potential novel T-cell-structured immuno-oncology therapiesAMSBIO launches Mimetix 3D cell tradition scaffolds for medication discovery, oncology researchTocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastomaCost of TOS was $2.5 million and $1.8 million for the years ended April 30, 2012 and 2011, respectively, an increase of $0.7 million, or 38 percent.The change allows Actavis to maintain a monopoly on the drug, even after patent expiration. According to the lawsuit, about 40 % of users have been forced to switch to the brand new form thus far. This shows how medicine today isn’t based on helping people get well but way more on controlling industry. A drug organization manipulating vulnerable sufferers and forcing doctors to improve treatment plans unnecessarily, only to protect corporate profits, is unethical and illegal, the lawyer general, Eric T.